Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies

Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) as well as multifocal motor neuropathies (MMNs). For the treatment of antibody deficiency syndromes...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Neurological Disorders 2016-07, Vol.9 (4), p.336-343
Main Authors: Leussink, Verena I., Hartung, Hans-Peter, Kieseier, Bernd C., Stettner, Mark
Format: Article
Language:English
Subjects:
Demyelination
Immunoglobulins
Inflammation
Intravenous administration
Progressive motor neuropathy
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) as well as multifocal motor neuropathies (MMNs). For the treatment of antibody deficiency syndromes, subcutaneous immunoglobulins (SCIgs) have represented a mainstay for decades. An emerging body of evidence suggests that SCIg might also exhibit clinical efficacy in CIDP and MMN. This article reviews the current evidence for clinical effectiveness, as well as safety of SCIg for the treatment of immune-mediated neuropathies, and addresses remaining open questions in this context. We conclude that despite the need for controlled long-term studies to demonstrate long-term efficacy of SCIg in immune-mediated neuropathies, SCIg may already represent a potential therapeutic alternative for selected patients.
ISSN:1756-2864
1756-2856
1756-2864
DOI:10.1177/1756285616641583